StackTerminal.Health

TB500 (TB4 / Thymosin Beta-4)

Thymosin beta-4 is studied in wound-healing contexts (preclinical + some clinical programs). 'TB500' in commerce is often loosely used; do not assume equivalence across products.

goal:recovery-sorenessgoal:muscle-recoverygoal:jointsconstraint:not-drug-test-safeevidence:lowstudy:mechanistic-animalpop:other-unclearform:other
Dosing model
FLATFixed dose (no body-weight scaling).
Min dose
Max dose
Rounding

Stacks containing TB500 (TB4 / Thymosin Beta-4)

Public community stacks that include this ingredient.

Explore all stacks →
recoveryskinresearch-only

Adds a copper peptide often discussed in cosmetic/skin contexts to a recovery/joint pairing. Evidence is indirect and component-based.

BPC-157
1mg
TB500 (TB4 / Thymosin Beta-4)
1mg
GHK-Cu
1mg
New
View
recoveryjointsresearch-only

Groups the two most commonly paired research peptides discussed in injury-repair circles; evidence is largely preclinical and not athlete-RCT grade.

BPC-157
1mg
TB500 (TB4 / Thymosin Beta-4)
1mg
New
View
Evidence
3 records
Wound healing
Rat full-thickness wound modelPreclinical animal study
Low

TB4 accelerated wound healing endpoints in a rat model compared with controls.

Dose:
Wound healing (reviewed clinical context)
Stasis and pressure ulcer clinical programsReview article
Low

A review summarizes phase 2 wound-healing programs reporting faster healing in those that did heal; note that these are not sports injury RCTs.

Dose:
Wound healing (clinical development)
Patients with venous stasis ulcersRegistered phase 2 trial (TB4 gel)
Low

TB4 gel has been studied in venous stasis ulcer indications; registry evidence supports clinical testing, though effect sizes depend on the specific trial and endpoint reporting.

Dose: Duration: Up to 84 days (per registry)
Forms
Lyophilized powder
Research material (vendor listing)